PD173074 [cytosol]

Stable Identifier
R-ALL-2038919
Type
ChemicalDrug
Compartment
Locations in the PathwayBrowser
General

PD173074 is potent pan-FGFR reversible inhibitor that interacts with residues in the ATP-binding pocket and inhibits tyrosine kinase activity and autophosphorylation (Mohammadi, 1998; Ezzat, 2005). PD173074 is not suitable for therapeutic use due to issues with toxicity.

Literature References
PubMed ID Title Journal Year
18757403 Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation

Byron, SA, Gartside, MG, Wellens, CL, Mallon, MA, Keenan, JB, Powell, MA, Goodfellow, PJ, Pollock, PM

Cancer Res 2008
9774334 Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain

Mohammadi, M, Froum, S, Hamby, JM, Schroeder, MC, Panek, RL, Lu, GH, Eliseenkova, AV, Green, D, Schlessinger, J, Hubbard, SR

EMBO J 1998
14715624 Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma

Trudel, S, Ely, S, Farooqi, Y, Affer, M, Robbiani, DF, Chesi, M, Bergsagel, PL

Blood 2004
18381441 FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival

Kunii, K, Davis, L, Gorenstein, J, Hatch, H, Yashiro, M, Di Bacco, A, Elbi, C, Lutterbach, B

Cancer Res 2008
Participant Of
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Cross References
ChEBI
Cite Us!